What Key Growth Drivers Are Shaping The Transthyretin Amyloidosis Treatment Market Forecast Toward $6.83 Billion?
Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
What Is The Present And Forecasted Size Of The Transthyretin Amyloidosis Treatment Market?
The transthyretin amyloidosis therapy market has seen robust growth in the past few years. Expected to expand from $4.59 billion in 2024 to $4.96 billion in 2025, it’s projected to achieve a compound annual growth rate (CAGR) of 8.0%. The previously observed growth can be credited to heightened disease awareness, advancements in diagnostic technology, developments in drug creation and ratification, patient support and advocacy, and cooperative research efforts.
The market for transthyretin amyloidosis treatment is anticipated to experience robust growth in the following years, escalating to $6.83 billion by 2029 with a compound annual growth rate (CAGR) of 8.3%. This predicted growth during the forecast period can be attributed to factors such as an enlarged therapeutic pipeline, increased genetic screening, global initiatives for rare disease awareness, strategies in personalized medicine, and enhanced accessibility to treatments. Key trends forecasted for this period include the advent of combination therapies, strategic collaborations for drug development, a focus on targeting peripheral and cardiac symptoms, the establishment of patient education programs, and the integration of tangible evidence into treatment protocols.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13129&type=smp
Which Market Dynamics Are Playing A Critical Role In The Growth Of The Transthyretin Amyloidosis Treatment Market?
The transthyretin amyloidosis treatment market is anticipated to expand due to increasing investments in research and development. These allocations are aimed at enhancing scientific understanding, the creation of latest technologies, innovation in products, and the refining of existing processes. Additional funding in this area facilitates the unearthing and development of novel treatment methods for transthyretin amyloidosis, ranging from innovative drugs to gene therapies and precision medicine techniques, which provide more successful, targeted treatments for patients. For example, Alnylam Pharmaceuticals, a US-based biopharmaceutical firm working on Vutrisiran, a treatment for ATTR amyloidosis, upped its investment in R&D to $883,015 in 2022 up from $792,156 in 2021, representing an increase of 11.49%. Consequently, the escalating investment in R&D is expected to catalyze the growth of the transthyretin amyloidosis treatment market.
What Are The Key Segment Trends Observed In The Transthyretin Amyloidosis Treatment Market?
The transthyretin amyloidosis treatmentmarket covered in this report is segmented –
1) By Type: Transthyretin Amyloidosis With Polyneuropathy (ATTR-PN); Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
2) By Drug: Tafamidis; Patisiran; Inotersen; Other Drugs
3) By Therapy: Targeted Therapy; Supportive Therapy; Pipeline Therapy
4) By Distribution Channel: Hospital Pharmacies; Specialty Pharmacies; Retail Pharmacies; Online Pharmacies
Subsegments:
1) By Transthyretin Amyloidosis With Polyneuropathy (ATTR-PN): Early-Stage ATTR-PN; Advanced-Stage ATTR-PN
2) By Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM): Mild ATTR-CM; Moderate ATTR-CM; Severe ATTR-CM
Which Disruptive Trends Are Driving Change Across The Transthyretin Amyloidosis Treatment Market?
Key players in the transthyretin amyloidosis treatment market are prioritizing the creation of unique and targeted treatments, such as orphan drugs, to improve patient outcomes and broaden treatment selection. Eplontersen is an orphan drug engineered specifically for battling transthyretin amyloidosis and often receives regulatory advantages to promote its progression. For example, Ionis Pharmaceuticals, Inc., a Canadian biotech research firm, was granted approval by The Food and Drug Administration (FDA) in March 2023 for their new drug application for Eplontersen. This novel orphan drug aims to fight familial transthyretin-mediated amyloid, causing progressive polyneuropathy. Eplontersen is a medicinal product designed to lessen the production of transthyretin (TTR) protein, tackling both hereditary and non-hereditary types of ATTR amyloidosis (amyloid transthyretin amyloidosis). In 2022, the FDA granted orphan drug status to Eplontersen.
Who Are The Leading Companies Driving The Transthyretin Amyloidosis Treatment Market?
Major companies operating in the transthyretin amyloidosis treatment market report are Pfizer Inc., Abbvie Inc., Sanofi S.A., Bristol Myers Squibb Company, AstraZeneca PLC, GSK PLC, Novo Nordisk A/S, Merck & Co. Inc., Astellas Pharma Inc., Alexion Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., PTC Therapeutics, Ionis Pharmaceuticals, Prothena Corporation PLC, BridgeBio Pharma Inc., Sorrento Therapeutics Inc., Intellia Therapeutics, Akcea Therapeutics Inc., Eidos Therapeutics Inc., Acrotech Biopharma Inc., Spectrum Pharmaceuticals Inc., Neurimmune AG, BELLUS Health Inc., Corino Therapeutics Inc., Celgene Corp, SOM Innovation Biotech S.A
Access The Complete Report Here:
Which Region Is Forecasted To Lead The Transthyretin Amyloidosis Treatment Market In The Coming Years?
North America was the largest region in the transthyretin amyloidosis treatment market in 2024. The regions covered in the transthyretin amyloidosis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=13129&type=smp
Browse Through More Reports Similar to the Global Transthyretin Amyloidosis Treatment Market 2025, By The Business Research Company
Pediatric Bladder Treatment Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/pediatric-bladder-treatment-global-market-report
Reversible Airway Diseases Treatment Global Market Report 2025
Urothelial Carcinoma Treatment Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
